Research Papers:

Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin

Anna V. Gaponova, Alexander Y. Deneka, Tim N. Beck, Hanqing Liu, Gregory Andrianov, Anna S. Nikonova, Emmanuelle Nicolas, Margret B. Einarson, Erica A. Golemis and Ilya G. Serebriiskii _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:19156-19171. https://doi.org/10.18632/oncotarget.13353

Metrics: PDF 1905 views  |   HTML 2390 views  |   ?  


Anna V. Gaponova1,2, Alexander Y. Deneka1,2, Tim N. Beck1,3, Hanqing Liu1,4, Gregory Andrianov2, Anna S. Nikonova1, Emmanuelle Nicolas1, Margret B. Einarson1, Erica A. Golemis1, Ilya G. Serebriiskii1,2

1Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA

2Department of Biochemistry and Biotechnology, Kazan Federal University, Kazan 420008, Russian Federation

3Department of Biochemistry & Molecular Biology, Program in Molecular and Cell Biology and Genetics, Drexel University College of Medicine, Philadelphia, PA 19129, USA

4Department of Pharmaceutics, Jiangsu University, School of Pharmacy, Jingkou District Zhenjiang, Jiangsu 212013, China

Correspondence to:

Ilya G. Serebriiskii, email: [email protected]

Erica A. Golemis, email: [email protected]

Keywords: platinating agents, resistance, DNA damage response, head and neck cancer

Received: September 08, 2016     Accepted: October 27, 2016     Published: November 15, 2016


Ovarian, head and neck, and other cancers are commonly treated with cisplatin and other DNA damaging cytotoxic agents. Altered DNA damage response (DDR) contributes to resistance of these tumors to chemotherapies, some targeted therapies, and radiation. DDR involves multiple protein complexes and signaling pathways, some of which are evolutionarily ancient and involve protein orthologs conserved from yeast to humans. To identify new regulators of cisplatin-resistance in human tumors, we integrated high throughput and curated datasets describing yeast genes that regulate sensitivity to cisplatin and/or ionizing radiation. Next, we clustered highly validated genes based on chemogenomic profiling, and then mapped orthologs of these genes in expanded genomic networks for multiple metazoans, including humans. This approach identified an enriched candidate set of genes involved in the regulation of resistance to radiation and/or cisplatin in humans. Direct functional assessment of selected candidate genes using RNA interference confirmed their activity in influencing cisplatin resistance, degree of γH2AX focus formation and ATR phosphorylation, in ovarian and head and neck cancer cell lines, suggesting impaired DDR signaling as the driving mechanism. This work enlarges the set of genes that may contribute to chemotherapy resistance and provides a new contextual resource for interpreting next generation sequencing (NGS) genomic profiling of tumors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13353